Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00040183
Other study ID # PA.3
Secondary ID
Status Completed
Phase Phase 3
First received June 21, 2002
Last updated January 8, 2018
Start date November 29, 2001
Est. completion date January 15, 2004

Study information

Verified date June 2015
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.


Recruitment information / eligibility

Status Completed
Enrollment 569
Est. completion date January 15, 2004
Est. primary completion date January 15, 2004
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility Inclusion Criteria:

Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas;cancer which is unresectable, locally advanced or metastatic.

Must have evidence of disease (clinical or radiological). Male or female, 18 years or older. Patients may have received prior radiation treatment for management of local disease providing that disease progression has been documented.

All toxicities have resolved, and the last fraction of radiation treatment was completed at least 4 weeks prior to randomization.

Patients may not have received prior chemotherapy, other then 5FU (+/- folic acid) or gemcitabine given concurrently with radiation treatment as a 'radiosensitiser.'

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tarceva (erlotinib HCl, OSI-774)


Locations

Country Name City State
Argentina Centro Medico Confidence Buenos Aires
Argentina Hospital Britanico Buenos Aires
Argentina Hospital Churruca Visca Buenos Aires
Argentina Hospital Italiano de Buenos Aires Buenos Aires
Argentina Instituto Alexander Fleming Buenos Aires
Argentina Instituto Oncologico Angel Roffo Buenos Aires
Australia Royal Adelaide Hospital Adelaide South Australia
Australia Ashford Cancer Centre Ashford South Australia
Australia Concord Hospital Concord New South Wales
Australia Frankston Hospital Frankston Victoria
Australia Austin & Repatriation Medical Centre Heidelberg Victoria
Australia Newcastle Mater Hospital HRMC Waratah New South Wales
Australia Prince of Wales Hospital Randwick New South Wales
Australia The Queen Elizabeth Hospital Woodville South South Australia
Belgium Institute Jules Bordet Brussels
Brazil Hospital Vera Cruz S/A Barro Preto Minas Gerais
Brazil Irmandade Santa Casa de Misericordia de Porto Alegre Porto Alegre RS
Brazil Nucleo de Oncolgia da Bahia Salvador BA
Brazil Hospital Israelita Albert Einstein Sao Paulo SP
Canada Cross Cancer Institute Edmonton Alberta
Canada QEII Health Sciences Centre Halifax Nova Scotia
Canada Hamilton Regional Cancer Centre Hamilton Ontario
Canada BC Cancer Centre for the Southern Interior Kelowna British Columbia
Canada Kingston Regional Cancer Centre Kingston Ontario
Canada London Regional Cancer Center London Ontario
Canada Credit Valley Hospital Mississauga Ontario
Canada Hopital Du Sacre-Coeur Montreal Quebec
Canada Hopital Maisonneuve-Rosemont Montreal Quebec
Canada Ottawa Regional Cancer Centre Ottawa Ontario
Canada Pentincton Regional Hospital Pentincton British Columbia
Canada Allan Blair Cancer Centre Regina Saskatchewan
Canada Saint John Regional Hospital Saint John New Brunswick
Canada Group Health Centre Saulte Ste. Marie Ontario
Canada Hotel Dieu Health Sciences HospitalNiagra St. Catharines Ontario
Canada Dr. H. Bliss Murphy Cancer Centre St. John's Newfoundland and Labrador
Canada Hopital Laval Ste-Foy Quebec
Canada Fraser Valley Cancer Centre Surrey British Columbia
Canada Princess Margaret Hospital Toronto Ontario
Canada St Joseph's Health Centre Toronto Ontario
Canada Toronto East General Hospital Toronto Ontario
Canada Toronto-Sunnybrook Regional Cancer Center Toronto Ontario
Canada BCCA VAncouver Centre Vancouver British Columbia
Canada BCCA- Vancouver Island Centre Victoria British Columbia
Canada CancerCare Manitoba (CCMB) Winnipeg Manitoba
Chile Clinica Las Condes Las Condes
Germany Charite Campus Virchow Klinikum Berlin
Germany Universitatsklinikum Essen Essen
Germany Tumor Biology Center Freiburg
Germany Universitatskliniken des Saarlands Innere Medizin II Hamburg
Germany Innere MedizinUniversitatsklinikum Heidelberg Heidelberg
Germany Universitatskliniken des Saarlands Homburg
Germany Medizinische Poliklinik der Universitaet Wurzburg Wurzburg
Greece Anticancer Hospital of Thessaloniki "THEAGENIO" Thessaloniki
Greece District General Hospital of Thessaloniki "HIPPOKRATION" Thessaloniki
Israel Rambam Medical Center Haifa
Israel Rabin Medical Center (Belinson Campus) Petach Tiqva
Israel Kaplan Medical Center Rehovot
Israel Sourasky Medical Center (Ichikov) Tel Aviv
Israel Chaim Sheba Medical Center Tel Hashomer
Italy Azienda Ospedaliera Universitaria Policlinico A.O.V.P. Oncologia Medica Palermo
Mexico Instituto Nacional De Cancerologia Mexico City
New Zealand Auckland Hospital Auckland
New Zealand Christchurch HospitalClinical Oncology Hospital Christchurch
Poland Great Poland Cancer Centre Poznan
Poland Dolnoslaskie Centrum Onkologii Wroclaw
Romania Oncology Institute Ion Chiricuta Cluj-Napoca
Romania St. Spiridon University Hospital Iasi
Romania Clinical County Hospital Sibiu Sibiu
Singapore National Cancer Centre Singapore
Singapore National University Hospital Singapore
Singapore Singapore General Hospital Singapore
United Kingdom Velindre Hospital Cardiff Wales
United Kingdom Russell's Hall HospitalDepartment of OncologyGeorgina Unit Dudley West Midlands
United Kingdom The Princess Royal Hospital Hull
United Kingdom North Middlesex Hospital London
United Kingdom St. Bartholomews Hospital London
United Kingdom Department of Medical Oncology Manchester
United Kingdom Newcastle General Hospital Newcastle-Upon-Tyne
United Kingdom ICRF Medical Oncology Unit Oxford Oxfordshire
United Kingdom Deanesly Centre Wolverhampton West Midlands
United States Annapolis Medical Specialists Annapolis Maryland
United States Arlington Cancer Centre Arlington Texas
United States Atlanta Cancer Center Atlanta Georgia
United States Southwest Regional Cancer Center Austin Texas
United States Sinai Hospital Baltimore Maryland
United States The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland
United States Mary Bird Perkins Cancer Center Baton Rouge Louisiana
United States Green Mountain Oncology Group Bennington Vermont
United States Alta Bates Comprehensive Cancer Center Berkeley California
United States Odyssey Research Services Bismarck North Dakota
United States New England Medical Center Boston Massachusetts
United States St Elizabeth Medical Center Boston Massachusetts
United States Charleston Hematology/Oncology Charleston South Carolina
United States Presbyterian Hospital Charlotte North Carolina
United States University Hospitals of Cleveland Cleveland Ohio
United States Hematology & Oncolgy Assoc of NE PA Dunmore Pennsylvania
United States Florida Cancer Specialists Fort Myers Florida
United States Arena Oncology Associates Great Neck New York
United States New Hampshire Oncology-Hematology PA Hooksett New Hampshire
United States MD Anderson Cancer Center Houston Texas
United States University of Iowa Hospital & Clinics Iowa City Iowa
United States Kansas City Oncology and Hematology Group Kansas City Missouri
United States University of Kansas Medical Center Kansas City Kansas
United States University of Kentucky Lexington Kentucky
United States St Barnabas Medical Center Livingston New Jersey
United States Loma Linda University Cancer Institute Loma Linda California
United States Metropolitan Hematology/Oncology Medical Group, Inc. Los Angeles California
United States UCLA Medical Center Los Angeles California
United States Norton Healthcare, Inc. Louisville Kentucky
United States DeQuattro Community Cancer Center Manchester Connecticut
United States J Gurtler, Hematology and Oncology Metairie Louisiana
United States Oncology Hematology Group of South Florida Miami Florida
United States Oncology of Wisconsin Milwaukee Wisconsin
United States University of Minnesota Minneapolis Minnesota
United States Sarah Cannon Cancer Center Nashville Tennessee
United States New Britain General Hospital New Britain Connecticut
United States New York University School of Medicine New York New York
United States St Luke's-Roosevelt Hospital New York New York
United States Eastern Connecticut Oncology Norwich Connecticut
United States Ocala Oncology Ocala Florida
United States Western Washington Oncology Inc. Olympia Washington
United States Onc/Hem Associates of Central Illinois Peoria Illinois
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Pennsylvania Oncology Hematology Associates Philadelphia Pennsylvania
United States University of Pennsylvania Cancer Center Philadelphia Pennsylvania
United States Berkshire Hematology & Oncology, PC Pittsfield Massachusetts
United States Chiles Research Cancer Center Portland Oregon
United States Hematology & Oncology Associates of Virginia, Ltd. Richmond Virginia
United States Interlakes Oncology & Hematology, P.C. Rochester New York
United States Kaiser Permanente San Diego California
United States Hematology Oncology Associates of Illinois Skokie Illinois
United States Highlands Oncology Group Springdale Arkansas
United States Baystate Medical Center Springfield Massachusetts
United States Carl and Dorothy Bennett Cancer Center Stamford Connecticut
United States Stony Brook University Hospital Stony Brook New York
United States Tampa General Hospital Tampa Florida
United States Arizona Clinical Research Center Tucson Arizona
United States Tyler Hematology Oncology PA Tyler Texas
United States Carle Cancer Center Urbana Illinois
United States Southwest Washington Medical Center Vancouver Washington

Sponsors (2)

Lead Sponsor Collaborator
OSI Pharmaceuticals Canadian Cancer Trials Group

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Belgium,  Brazil,  Canada,  Chile,  Germany,  Greece,  Israel,  Italy,  Mexico,  New Zealand,  Poland,  Romania,  Singapore,  United Kingdom, 

References & Publications (1)

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT05305001 - Germline Mutations Associated With Hereditary Pancreatic Cancer in Unselected Patients With Pancreatic Cancer in Mexico
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT06054984 - TCR-T Cells in the Treatment of Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Terminated NCT03140670 - Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy Phase 2
Terminated NCT00529113 - Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer Phase 1
Recruiting NCT05168527 - The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05391126 - GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care N/A
Terminated NCT03300921 - A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer Phase 1
Completed NCT03153410 - Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas Early Phase 1
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Recruiting NCT05679583 - Preoperative Stereotactic Body Radiation Therapy in Patients With Resectable Pancreatic Cancer Phase 2
Recruiting NCT04183478 - The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer Phase 2/Phase 3
Terminated NCT03600623 - Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Early Phase 1
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Recruiting NCT05351983 - Patient-derived Organoids Drug Screen in Pancreatic Cancer N/A
Completed NCT04290364 - Early Palliative Care in Pancreatic Cancer - a Quasi-experimental Study